Author: a16z Podcast

  • Don’t Call it a Brain in a Dish!

    Our understanding of the human brain and its disorders has always been limited by our lack of access to living, human, developing brain tissue. For the first time, that’s changing. In this episode, Sergiu Pasca, Professor of Behavioral Science at Stanford, talks with a16’z General Partner Vijay Pande and Hanne Tidnam about the wild new tech that’s pioneering a whole new approach to understanding the brain: brain organoids.

    So what are brain organoids, what are the scientific breakthroughs that lead to their creation, and how can we use them best? The conversation starts with the existing models we have used to learn about the living brain, from genetic studies to autopsies to primates—and what this new model now brings us: the ability to study the human brain, both how it develops and what goes wrong in certain disorders, with human brain tissue “alive” in a dish. We talk about what these organoids can and can’t do; what they’re good for understanding and where that understanding becomes limited; why calling these “brains in a dish” or “mini-brains” isn’t the right terminology at all; and finally, how far can this new tool and model be taken now and in the future, leading us closer towards understanding psychology itself on a molecular level.

    Image: Brain organoids derived in the Pasca Lab at Stanford University.

  • Pandemics: Early Detection, Networks, Spreaders

    Pandemics are predictable; what’s not predictable is the intensity, or the precise timing of arrival. That’s where early detection — not just rapid warning (as with something like Google Flu Trends back in the day), or even delayed warnings (as with CDC flu trackers and such) — comes in. Because unfortunately, many disease tracking efforts old and new are “like watching the weather forecast a week after you’ve experienced that weather”, observes a16z general partner Jorge Conde.

    And this matters for saving lives; for load balancing and allocating resources (ventilators, PPE, supplies); getting back to work; and much more. Even a two-week advantage could have made a huge difference! Which is what sociologist and physician Nicholas Christakis (who directs the Human Nature Lab, part of the Yale Institute for Network Science, and also author of the book Blueprint) learned from the H1N1 pandemic. Specifically, the role of social network “sensors” — where friends in one’s network graph can be like canaries in the proverbial coal mine to help detect pandemics earlier.

    In fact, the lab recently released an app called Hunala (which uses information crowdsourced among networks) to determine one’s likelihood of contracting flu/ influenza-like or other respiratory illnesses through a personalized daily assessment of risk. Kind of like Waze, but for illnesses not car accidents. So in this episode of the a16z Podcast, the two take that analogy far. They also discuss the role of other mobility data and population flows in China for where and when the pandemic spread; the nuances behind “superspreaders”; how bad is the coronavirus, really; and the near future of “bio-surveillance” — not just from a personal risk perspective, but from a global public-health perspective… Can we get the holy grail here without sacrificing privacy and agency?

  • Podcasting and the Future of Audio

    This podcast (first recorded in 2019, now being rerun) — is a podcast about podcasting: But it’s really all about audio. A lot’s changed… and a lot hasn’t. 

    How do we define “podcasts”; how does the feeds ecosystem currently work; what content and entertainment experiments might change how people not just consume, but create, in the medium? Not to mention monetize, discover, etc… 

    Nick Quah, writer and publisher of Hot Pod (also at Vulture) joins a16z general partner Connie Chan — and editor in chief (and showrunner of the a16z Podcast) Sonal Chokshi — to talk about all this and more in this hallway-style jam. 

     

    The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates.

    This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investor or prospective investor, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund which should be read in their entirety.)

    Past performance is not indicative of future results. Any charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Please see https://a16z.com/disclosures for additional important information.

  • Growth in Turbulent Times

     In normal times, every company operates against some hypothetical growth model—a data-driven framework that describes how your product grows and how you acquire new users. These, of course, are not normal times. In the fallout from the pandemic, most founders and CEOs are in the process of completely revamping their growth models from the bottom up amid new and unpredictable consumer behavior. 

    This episode explores how to think about growth in turbulent times, according to two growth experts: a16z general partner Andrew Chen, who previously led the growth team at Uber, and Brian Balfour, formerly the VP of Growth at HubSpot, now the founder and CEO of Reforge, a masterclass in growth strategies (in conversation with host Lauren Murrow).

    The discussion spans four sections: first, how to reassess your existing growth model, particularly when, as Brian says, the data is “completely messed”; next, we drill down into strategy and tactics for surviving the current crisis and talk about how founders can pursue growth even in the midst of widespread uncertainty and cutbacks. Third, we look ahead to discuss scenario planning and how leaders can forge a path forward. Finally, we zoom out and assess the big picture: how various categories of company may be impacted long-term, how this crisis compares to 2008 (and what that means for early-stage founders), and the industries and business models that are now prime for growth. 

     

  • Journal Club: Using CRISPR to Prevent Coronavirus and Influenza Infection

    In this episode of a16z bio Journal Club, general partner Vijay Pande, bio deal team partner Andy Tran, and bio editor Lauren Richardson discuss a novel CRISPR-Cas-based anti-viral strategy.

    The discussion covers the differences between this newly developed prophylactic strategy, traditional vaccines, and anti-viral drugs; how this strategy can be engineered to target a huge range of coronavirus and influenza strains; and the next steps needed to go from paper to practice:

    a16z Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature — what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). You can find all these episodes at a16z.com/journalclub.

  • What’s Next in Gaming

    Video game technology has evolved into a global phenomenon that extends far beyond entertainment. In this episode, John Riccitiello, CEO of the game software development company Unity Technologies, is interviewed by a16z general partner Andrew Chen on the rise of esports and streaming, the potential of cloud gaming, and  far-reaching applications for game technology. This conversation originally took place at our most recent innovation conference, the a16z Summit.

  • Undruggable Drugs

    In this episode of the a16z Podcast, we take a deep dive into the world of drug development—specifically “undruggable drugs”: a category of protein, protein family or even piece of RNA that’s so difficult to target that many researchers don’t even want to touch it. 

    Jay Bradner, President of the Novartis Institute for BioMedical Research, shares with a16z General Partners Jorge Conde and Vijay Pande, and a16z’s Hanne Tidnam, all the new tools, technologies and breakthroughs which are causing the science of therapeutics to explode in some of these areas where it’s been incredibly difficult (even impossible) in the past. From molecular glues to cell and gene therapies, Bradner shares the behind-the-scenes science stories of what it really takes to make a new drug that shatters the category of an “undruggable” target. 

  • The Next Generation of Cultural Influencers in Tech

    This episode—which originally took place as a live event—is a conversation between Seattle Seahawks linebacker Bobby Wagner and a16z Cultural Leadership Fund partner Chris Lyons. Wagner is known for his power on the field and his business acumen off it. Last year, he negotiated his own three-year, $54 million contract extension to become the highest-paid middle linebacker in the NFL. In this candid conversation, Wagner and Lyons discuss how to identify standout companies and talent (for better or worse), the growing influence of cultural leaders in tech, and the potential of “shared genius.”

  • The Chief Security Officer in (and out of) a Crisis

    The Chief Security Officer (CSO/CISO) used to manage on-premise servers, now the information they have to secure has migrated to the cloud. As the responsibility of CSOs has expanded, the role has moved from technical IT to the boardroom. How do the best CSOs prepare for and respond to a crisis, from redteaming to comms? What responsibility should cloud & SaaS vendors, not to mention the government, have in security and data breaches?  And how is the role going to evolve in the next five years? 

    At our a16z Innovation Summit last year, we sat down with two security leaders whose career has evolved as the role has – Joe Sullivan, former CSO at Uber and Facebook, now at Cloudflare and Joel de la Garza, current security partner at a16z, formerly CISO at Box. 

  • Journal Club: Finding New Antibiotics with Machine Learning, What Coronavirus Structures Tell Us

    a16z Journal Club (part of the a16z Podcast), curates and covers recent advances from the scientific literature — what papers we’re reading, and why they matter from our perspective at the intersection of biology & technology (for bio journal club). This inaugural episode covers 2 different topics, in discussion with Lauren Richardson:

    0:26 #1 identifying new antibiotics through a novel machine-learning based approach — a16z general partner Vijay Pande and bio deal partner Andy Tran discuss the business of pharma; the specific methods/  how it works; and other applications for deep learning in drug discovery and development based on this paper:

    • A Deep Learning Approach to Antibiotic Discovery” in Cell (February 2020), by Jonathan Stokes, Kevin Yang, Kyle Swanson, Wengong Jin, Andres Cubillos-Ruiz, Nina Donghia, Craig MacNair, Shawn French, Lindsey Carfrae, Zohar Bloom-Ackermann, Victoria Tran, Anush Chiappino-Pepe, Ahmed Badran, Ian Andrews, Emma Chory, George Church, Eric Brown, Tommi Jaakkola, Regina Barzilay, James Collins

    11:43 #2 characterizing the novel coronavirus causing the COVID-19 pandemic — a16z bio deal partner Judy Savitskaya shares what we can learn from the protein structures; the relationship to the 2002-2004 SARS epidemic; and more based on these two research articles: 

    You can find these episodes at a16z.com/journalclub.